Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04542590 · ClinicalTrials.gov registry record
Natural History of Patients With PH3 and a History of Stone Events
A clinical trial, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- Completed
- Registry status
- 7
- Enrollment target
NCT04542590 is a clinical trial that has completed, run by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company. The registered enrollment target is 7 participants.
The verdict
NCT04542590 has completed, sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company.
- COMPLETED
- Registry status
- 7 participants
- Enrollment target
Study Summary
This is a natural history study of adults, adolescents, and children (starting at birth) with genetically confirmed primary hyperoxaluria type 3 (PH3) who have a history of stone events during the last 3 years and/or the presence of pre existing stones detected by renal ultrasound at screening.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-09-09 |
| Est. Completion | 2024-07-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04542590
The ClinicalTrials.gov registry entry for NCT04542590 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04542590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04542590 about?
NCT04542590 is a clinical study titled "Natural History of Patients With PH3 and a History of Stone Events". This is a natural history study of adults, adolescents, and children (starting at birth) with genetically confirmed primary hyperoxaluria type 3 (PH3) who have a history of stone events during the last 3 years and/or the presence of pre existing stones detected by renal ultrasound at screening.
What is the current status of trial NCT04542590?
This trial is currently completed. The enrollment target is 7 participants. The study started on 2021-09-09. Estimated completion is 2024-07-23.
Who is sponsoring clinical trial NCT04542590?
This trial is sponsored by Dicerna Pharmaceuticals, Inc., a Novo Nordisk company, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.